Coastal Infusion Administers Skyrizi^®

Skyrizi (risankizumab) is used to treat moderate-to-severe plaque psoriasis, and psoriatic arthritis, when traditional disease-modifying anti-rheumatic drugs (DMARDs) have proven ineffective or have led to intolerable side effects. Skyrizi has also been approved to treat moderate-to-severe Crohn’s Disease, when conventional or biological treatments have not yielded satisfactory results or have caused unacceptable side effects.

The active substance in Skyrizi, risankizumab, is a monoclonal antibody that is designed to attach to interleukin-23 (IL-23) and block its activity. By blocking the action of IL-23, risankizumab reduces inflammation and other symptoms associated with these conditions.

What It Treats

• Crohn's Disease
• Plaque Psoriasis
• Psoriatic Arthritis

Prescribed By

Skyrizi is most often prescribed by Dermatologists and Rheumatologists.

How it's Administered

Skyrizi is administered by subcutaneous injection. Skyrizi injections take only a few minutes.

Frequency

Skyrizi is generally administered every 12 weeks after two starter doses, four weeks apart.

Related Drugs

Bimzelx, Cosentyx, Skyrizi, Tremfya

Additional Resources

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies